← All trials
NCT00209222
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 1, 2004
- Primary completion
- Dec 1, 2014
- Completion date
- Dec 1, 2014
- First posted
- —
- Last posted
- —
- Enrollment
- 360
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- European Mantle Cell Lymphoma NetworkLead sponsor
- University of ParisOverall official - principal investigator
- German Low Grade Lymphoma Study GroupCollaborator
- The Lymphoma Study AssociationCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.